SynthesisInternational journal of chronic obstructive pulmonary disease2011
Safety of indacaterol in the treatment of patients with COPD.
Synthesis in International journal of chronic obstructive pulmonary disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials.International journal of chronic obstructive pulmonary disease · 2019Pooled it
- Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis.PloS one · 2013Pooled it
- Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2012Pooled it
- Comprehensive assessment of the safety of olodaterol 5 µg in the RespimatNPJ primary care respiratory medicine · 2017Trial
- One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.Chest · 2014Trial
- Real-world Safety and Efficacy of Indacaterol Maleate in Patients with Chronic Obstructive Pulmonary Disease: Evidence from the Long-term Post-marketing Surveillance in Japan.Internal medicine (Tokyo, Japan) · 2021Article
- Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea.Tuberculosis and respiratory diseases · 2017Article
- Global scientific collaboration in COPD research.International journal of chronic obstructive pulmonary disease · 2017Article
- The law of mass action and the pharmacological concentration-effect curve: resolving the paradox of apparently non-dose-related adverse drug reactions.British journal of clinical pharmacology · 2016Review
- Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.Basic & clinical pharmacology & toxicology · 2015Review
- A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study.International journal of chronic obstructive pulmonary disease · 2015Observational
- Positioning new pharmacotherapies for COPD.International journal of chronic obstructive pulmonary disease · 2015Review
- Review
- New developments in the management of COPD: clinical utility of indacaterol 75 μg.International journal of chronic obstructive pulmonary disease · 2014Review
- Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease.Journal of thoracic disease · 2013Review
- Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.Respiratory research · 2013Article
- Chronic obstructive pulmonary disease in China: the potential role of indacaterol.Journal of thoracic disease · 2013Article
- The role of indacaterol for chronic obstructive pulmonary disease (COPD).Journal of thoracic disease · 2013Article
- Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Lung India : official organ of Indian Chest Society · 2013Article
- Indacaterol-induced severe constipation and abdominal pain: is there a role for colonic β3-adrenoceptors?BMJ case reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePooled data were analyzed to evaluate the safety and tolerability of indacaterol, a once-daily inhaled long-acting β(2)-agonist for chronic obstructive pulmonary disease (COPD). PATIENTS AND
methodsData were pooled from clinical studies of 3-12 months' duration in patients with moderate-to-severe COPD receiving double-blind indacaterol 75 μg (n = 449), 150 μg (n = 2611), 300 μg (n = 1157), or 600 μg once daily (n = 547); formoterol 12 μg twice daily (n = 556); salmeterol 50 μg twice daily (n = 895); placebo (n = 2012); or tiotropium 18 μg once daily, given open label or blinded (n = 1214). Outcomes were adverse events, serious adverse events and deaths, plasma potassium, blood glucose, and QTc interval and vital signs.
resultsThe commonest adverse events with indacaterol were COPD worsening, nasopharyngitis, and headache; most cases were mild or moderate and incidence was generally similar to placebo and other active treatments. The risk of acute respiratory serious adverse events (leading to hospitalization, intubation, or death) was not significantly increased with any of the active treatments compared with placebo. COPD exacerbation rates (analyzed in the intent-to-treat population) were significantly reduced with all active treatments versus placebo. Hazard ratios versus placebo for major cardiovascular adverse events were < 1 for all indacaterol doses. Notable values for vital signs and measures of systemic β(2)-adrenoceptor activity were rare with indacaterol. The number of deaths adjusted per patient-year was lower with indacaterol (all doses combined) than with placebo (relative risk 0.21 [95% confidence interval 0.07-0.660], P = 0.008).
conclusionIndacaterol has a good profile of safety and tolerability that is appropriate for the maintenance treatment of patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.